Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg and Rituximab for Desensitization in Kidney Transplant
NCT00986947Phase 2Terminated
- Sponsor
- Johns Hopkins University
- Start
- Sep 2009
- Primary completion
- Jul 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of intravenous human immunoglobulin, rituximab in end stage renal disease (ESRD), sponsored by Johns Hopkins University. Started Sep 2009; status: terminated.
02
Drugs
intravenous human immunoglobulinrituximab
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT00986947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00986947.